# Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)

> **NCT01950299** · PHASE2,PHASE3 · COMPLETED · sponsor: **Virginia Commonwealth University** · enrollment: 99 (actual)

## Conditions studied

- Acute Myocardial Infarction

## Interventions

- **DRUG:** Anakinra 100 mg
- **DRUG:** Anakinra 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01950299
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-01
- **Primary completion:** 2018-12-23
- **Final completion:** 2018-12-23
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2019-12-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01950299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01950299, "Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01950299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*